Agenus Inc. (AGEN) Stock

Agenus Inc. (AGEN) is a Healthcare stock trading at $3.00 (as of 2026-06-18), with a market capitalization of $134.09M and a trailing P/E of 1.6. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Agenus Inc. is a clinical-stage immuno-oncology company that discovers and develops immuno-oncology products. Its portfolio includes an antibody expression/display platform and related display technologies, as well as vaccine programs and multiple therapeutic candidates targeting immune checkpoints and the tumor microenvironment for patients in the U.S. and internationally.

Valuation — source: SEC EDGAR (first-party)
Price	$3.00
Market Cap	$134.09M
P/E Ratio	1.6
EV / EBITDA	10.5
Price / Book	-0.60
Price / Sales	1.11
DCF Value (model)	$-35.31
DCF Upside vs Price	-1277.0%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$114.20M
Net Margin	-2.7%
Return on Equity	-27.4%
Debt / Equity	-0.26
Current Ratio	0.38
Revenue Growth (YoY)	10.4%
EPS Growth (YoY)	-100.0%
FCF Growth (YoY)	-51.4%

Financial Health — source: SEC EDGAR
Altman Z-Score	-14.13 (distress)
Piotroski F-Score	3/9 (weak)

Valuation vs Sector & Industry
Stock P/E	1.6
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-92.3%
vs Industry	-90.5%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	BlackRock Fund Advisors ($9.68M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Garo H. Armen
Employees	316
Country	US
IPO Date	2000-02-08

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.